|
Home:
Recent
Publications: Recent
Publications 2000
Miscellaneous
Topics l Antiestrogens,
Tamoxifen l Aromatase
Inhibitors
Faslodex® (Fulvestrant,
ICI182180)
lOvarian
Ablation/Suppression
Estrogen/Progesterone Receptors
Miscellaneous
articles
Static
disease on anastrozole provides similar benefit as objective response
in patients with advanced breast cancer.
Robertson,
J. F. R.; Howell, A.; Buzdar, A.; von Euler, M., and Lee, D.. Breast
Cancer Research & Treatment. 58(2):157-162, 1999 Nov.
Eye
problems in breast cancer patients treated with tamoxifen.
Breast
Cancer Research & Treatment. 60(2):167-172, 2000 Mar.
Symptoms
associated with oophorectomy and tamoxifen treatment fo breast cancer
in premenopausal Vietnamese women.
Love,
R. R.; Duc, N. B.; Binh, N. C.; Van Dinh, N., and Havighurst, T.
C. (Reprint available from: Love RR Univ Wisconsin, Ctr Comprehens
Canc Madison, WI 53706 USA). Breast Cancer Research & Treatment.
58(3):281-286, 1999 Dec.
Endocrine
therapies for patients with recurrent breast cancer: Predictive
factors for responses to first- and second-line endocrine therapies.
Kurebayashi,
J.; Sonoo, H.; Inaji, H.; Nishimura, R.; Iino, Y.; Toi, M.; Kobayashi,
S., and Saeki, T. (Reprint available from: Kurebayashi J Kawasaki
Med Sch, Dept Breast & Thyroid Surg 577 Matsushima Okayama 7010192
Japan).. Oncology. 59(Suppl 1):31-37, 2000.
Influence
of estrogen receptor variants on the determination of ER status
in human breast cancer.
Huang,
A. H.; Leygue, E.; Dotzlaw, H.; Murphy, L. C., and Watson, P. H.
(Reprint available from: Watson PH Univ Manitoba, Dept Pathol Winnipeg
MB R3T 2N2 Canada). Breast Cancer Research & Treatment. 58(3):219-225,
1999 Dec.
The
pure antiestrogen ICI 182780 is more effective in the induction
of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7
cells.
Diel,
P.; Smolnikar, K., and Michna, H. (Reprint available from: Diel
P DSHS Cologne, Dept Morphol & Tumor Res Carl Diemer Weg 6 D-50927
Cologne Germany).. Breast Cancer Research & Treatment. 58(2):87-97,
1999 Nov.
Cyclophosphamide,
methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression
as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal
breast cancer patients: Results of the Italian Breast Cancer Adjuvant
Study Group 02 Randomized Trial.
Boccardo,
F.; Rubagotti, A.; Amoroso, D.; Mesiti, M.; Romeo, D.; Sismondi,
P.; Giai, M.; Genta, F.; Pacini, P.; Distante, V.; Bolognesi, A.;
Aldrighetii, D., and Farris, A. Journal of Clinical Oncology. 18(14):2718-2727,
2000 Jul.
The
excess burden of breast carcinoma in minority and medically underserved
communities - Application, research, and redressing institutional
racism
Shinagawa,
S. M.. Cancer. 88(5 Suppl S):1217-1223, 2000 Mar 1.
Phytoestrogens
and adjuvant endocrine treatment of breast cancer.
This,
P. and Magdelenat, H.. Journal of Clinical Oncology. 18(14):2792,
2000 Jul. No abstract
Oestrogen
and growth factor cross-talk and endocrine insensitivity and acquired
resistance in breast cancer [Review].
Nicholson,
R. I. and Gee, J. M. W. (Reprint available from: Nicholson RI Univ
Wales, Coll Med, Tenovus Canc Res Ctr Cardiff CF14 4XX S Glam Wales).
British Journal of Cancer. 82(3):501-513, 2000 Feb. No abstract
Safety
and tolerability of endocrine therapies used in the treatment of
advanced breast cancer. Bland, K. I. and Buzdar, A. U. Annals
of Surgical Oncology. 6(8 Suppl S) 12S-13S, 1999 Dec. NO ABSTRACT
Future
directions in endocrine treatment of advanced breast cancer.
Annals of Surgical Oncology. 6(8 Suppl S):14S-16S, 1999 Dec. NO
ABSTRACT
Current
status of endocrine therapy for advanced breast cancer.
Annals of Surgical Oncology. 6(8 Suppl S):4S-7S, 1999 Dec. NO
ABSTRACT
Top
of Page
Antiestrogens,
tamoxifen
Selective
estrogen receptor modulators: Structure, function, and clinical
use [Review].
Osborne,
C. K. and Fuqua, S. A. W. Journal of Clinical Oncology. 18(17):3172-3186,
2000 Sep.
Differences
in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitiveand
-resistant breast carcinomas: preclinical and first clinical investigations.
Naundorf,
H.; Jost-Reuhl, B.; Becker, M.; Reuhl, T.; Neumann, C., and Fichtner,
I. (Reprint available from: Fichtner I Max Delbruck Ctr Mol Med
Robert Rossle Str 10 D-13125 Berlin Germany).. Breast Cancer Research
& Treatment. 60(1):81-92, 2000 Mar.
Development
and characterization of a tamoxifen resistant breast carcinoma xenograft.
Naundorf,
H.; Becker, M.; Lykkesfeldt, A. E.; Elbe, B.; Neumann, C.; Buttner,
B., and Fichtner, I (Reprint available from: Fichtner I Max Delbruck
Ctr Mol Med Robert Rossle Str 10 D-13092 Berlin Germany).. British
Journal of Cancer. 82(11):1844-1850, 2000 Jun.
Combined
treatment with buserelin and tamoxifen in premenopausal metastatic
breast cancer: A randomized study.
Klijn,
J. G. M.; Beex LVAM; Mauriac, L.; van Zijl, J. A.; Veyret, C.; Wildiers,
J.; Jassem, J.; Piccart, M.; Burghouts, J.; Becquart, D.; Seynaeve,
C.; Mignolet, F., and Duchateau, L. (Reprint available from: Klijn
JGM Dr Daniel den Hoed Klin, Rotterdam Canc Inst, Dept Med Oncol
Groene Hilledijk 301 NL-3075 EA Rotterdam Netherlands). Journal
of the National Cancer Institute. 92(11):903-911, 2000 Jun 7.
Effects
of high dose raloxifene in selected patients with advanced breast
carcinoma.
Gradishar,
W.; Glusman, J.; Lu, Y.; Vogel, C.; Cohen, F. J., and Sledge, G.
W. Cancer. 88(9):2047-2053, 2000 May 1.
Effects
of adjuvant tamoxifen on the endometrium in postmenopausal women
with breast cancer: A prospective long-term study using transvaginal
ultrasound.
Gerber,
B.; Krause, A.; Muller, H.; Reimer, T.; Kulz, T.; Makovitzky, J.;
Kundt, G., and Friese, K. Journal of Clinical Oncology. 18(20):3464-3470,
2000 Oct 15.
Results
of two or five years of adjuvant tamoxifen correlated to steroid
receptor and S-phase levels.
Ferno,
M.; Stal, O.; Baldetrop, B.; Hatschek, T.; Kallstrom, A. C.; Malmstrom,
P.; Nordenskjold, B., and Ryden, S.. Breast Cancer Research &
Treatment. 59(1):69-76, 2000 Jan.
Tamoxifen
adjuvant treatment duration in early breast cancer: Initial results
of a randomized study comparing short-term treatment with long-term
treatment.
Delozier,
T.; Spielmann, M.; Mace-Lesec'h, J.; Janvier, M.; Hill, C.; Asselain,
B.; Julien, J. P.; Weber, B.; Mauriac, L.; Petit, J. C.; Kerbrat,
P.; Malhaire, J. P.; Vennin, P.; Leduc, B., and Namer, M.. Journal
of Clinical Oncology. 18(20):3507-3512, 2000 Oct 15.
Biomarkers
and outcome after tamoxifen treatment in node-positive breast cancers
from elderly women.
Daidone,
M. G.; Luisi, A.; Martelli, G.; Benini, E.; Veneroni, S.; Tomasic,
G.; De Palo G, and Silvestrini, R. (Reprint available from: Daidone
MG Ist Nazl Studio & Cura Tumori Via Venezian 1 I-20133 Milan
Italy). British Journal of Cancer. 82(2):270-277, 2000 Jan.
Effect
of adjuvant tamoxifen on the endometrium in women with breast cancer:
A prospective study using office endometrial biopsy.
Barakat,
R. R.; Gilewski, T. A.; Almadrones, L.; Saigo, P. E.; Venkatraman,
E.; Hudis, C., and Hoskins, W. J. Journal of Clinical Oncology.
18(20):3459-3463, 2000 Oct 15.
Surveillance
for uterine abnormalities in tamoxifen-treated breast carcinoma
survivors - A community-based study.
Althuis,
M. D.; Sexton, M.; Langenberg, P.; Bush, T. L.; Tkaczuk, K.; Magaziner,
J., and Khoo, L. Cancer. 89(4):800-810, 2000 Aug 15.
Similarities
and distinctions in the mode of action of different classes of antioestrogens
[Review].
Wakeling,
A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar.
Approaches
targeted to estrogen receptors for treatment of tamoxifen-resistant
breast cancer: A brief overview.
Terakawa, N. (Reprint available from: Terakawa N Tottori Univ,
Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan)..
Oncology. 59(Suppl 1):3-4, 2000. No abstract
Preliminary
assessment of cognitive function in breast cancer patients treated
with tamoxifen.
Paganini-Hill,
A. and Clark, L. J. Breast Cancer Res.earch & Treatment. 64(2):165-176,
2000 Nov.
Symposium
overview: Estrogens and antiestrogens in managing the patient with
breast cancer.
Newman,
L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary,
S. E. (Reprint available from: Singletary SE Univ Texas, MD Anderson
Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX
77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep.
The
ovary: cysts, screening, and tamoxifen.
Mourits,
M. J. E.; van der Zee, A. G. J.; Willemse, P. H. B., and de Vries,
E. G. E. (Reprint available from: de Vries EGE Univ Groningen Hosp,
Dept Med Oncol POB 30 001 NL-9700 RB Groningen Netherlands). Lancet.
355(9220):2078-2079, 2000 Jun 10.
Concentrations
of tamoxifen and its major metabolites in hormone
responsive and resistant breast tumours.
MacCallum,
J.; Cummings, J.; Dixon, J. M., and Miller, W. R. (Reprint available
from: MacCallum J Napier Univ, Dept Life Sci Merchiston Campus,Colinton
Rd Edinburgh EH10 5DT Midlothian Scotland).. British Journal of
Cancer. 82(10):1629-1635, 2000 May.
How
is tamoxifen's action subverted?
Jordan, V. C. (Reprint available from: Jordan VC Northwestern
Univ, Sch Med, Rober H Lurie Comprehens Canc Ctr 303 E Chicago Ave,Olson
Pavil 8258 Chicago, IL 60611 USA). Journal of the National Cancer
Institute. 92(2):92-94, 2000 Jan 19. No abstract
Serum
lipid levels during and after adjuvant toremifene or tamoxifen therapy
for breast cancer.
Joensuu,
H.; Holli, K.; Oksanen, H., and Valavaara, R. (Reprint available
from: Joensuu H Univ Helsinki, Cent Hosp, Dept Oncol Haartmaninkatu
4,POB 180 FIN-00029 Helsinki Finland). Breast Cancer Research &
Treatment. 63(3):225-234, 2000 Oct.
One
step forward or one step back with tamoxifen?
Gelmon, K. (Reprint available from: Gelmon K British Columbia
Canc Agcy Vancouver BC V5Z 4E6 Canada). Lancet. 356(9233):868-869,
2000 Sep 9. No abstract
Endometrial
protection from tamoxifen-stimulated changes by a evonorgestrel-releasing
intrauterine system: a randomised controlled trial.
Gardner,
F. J. E.; Konje, J. C.; Abrams, K. R.; Brown, L. J. R.; Khanna,
S.; Al-Azzawi, F.; Bell, S. C., and Taylor, D. J.. Lancet. 356(9243):1711-1717,
2000 Nov 18.
Combined
endocrine therapy for breast cancer - New life for an old idea?
Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins
Oncol Ctr 1650 Orleans St, Rm 409 Baltimore, MD 21231 USA). Journal
of the National Cancer Institute. 92(11):859-860, 2000 Jun 7. No
abstract
Risk
and prognosis of endometrial cancer after tamoxifen for breast cancer.
Bergman,
L.; Beelen, M. L. R.; Gallee, M. P. W.; Hollema, H.; Benraadt, J.,
and van LeeuwenF. E.. Lancet. 356(9233):881-887, 2000 Sep 9.
Top
of Page
Aromatase
Inhibitors
Combined
endocrine treatment of elderly postmenopausal patients with metastatic
breast cancer - A randomized trial of tamoxifen vs. tamoxifen plus
aminoglutethimide and hydrocortisone and tamoxifen plu fluoxymesterone
in women above 65 years of age.
Rose,
C.; Kamby, C.; Mouridsen, H. T.; Andersson, M.; Bastholt, L.;
Moller, K. A.; Andersen, J.; Munkholm, P.; Dombernowsky, P., and
Christensen, I. J. (Reprint available from: Rose C Odense Univ Hosp,
Dept Oncol DK-5000 Odense C Denmark). Breast Cancer Research &
Treatment. 61(2):103-110, 2000 May.
Activity
of exemestane in metastatic breast cancer after failure of nonsteroidal
aromatase inhibitors: A phase II trial.
Lonning,
P. E.; Bajetta, E.; Murray, R.; Tubiana-Hulin, M.; Eisenberg, P.
D. Mickiewicz, E.; Celio, L.; Pitt, P.; Mita, M.; Aaronson, N. K.;
Fowst, C.; Arkhipov, A.; di Salle, E.; Polli, A., and Massimini,
G. Journal of Clinical Oncology. 18(11):2234-2244, 2000 Jun.
Exemestane
is superior to megestrol acetate after tamoxifen failure in postmenopausal
women with advanced breast cancer: Results of a phase III randomized
double-blind trial.
Kaufmann,
M.; Bajetta, E.; Dirix, L. Y.; Fein, L. E.; Jones, S. E.; Zilembo,
N.; Dugardyn, J. C.; Nasurdi, C.; Mennel, R. G.; Cervek, J.; Fowst,
C.; Polli, A.; di Salle, E.; Arkhipov, A.; Piscitelli, G.; Miller,
L. L., and Massimini, G. Journal of Clinical Oncology. 18(7):1399-1411,
2000 Apr.
Cellular
responses of mammary carcinomas to aromatase inhibitors: Effects
of vorozole. Breast.
Christov,
K.; Shilkaitis, A.; Green, A.; Mehta, R. G.; Grubbs, C.; Kelloff,
G., and Lubet, R. (Reprint available from: Christov K Univ Illinois,
Dept Surg Oncol 840 S Wood St,M-C 820 Chicago, IL 60612 USA). Cancer
Research & Treatment. 60(2):117-128, 2000 Mar.
Anastrozole
versus tamoxifen as first-line therapy for advanced breast cancer
in 668 postmenopausal women: Results of the tamoxifen or arimidex
randomized group efficacy and tolerability study.
Bonneterre,
J.; Thurlimann, B.; Robertson, J. F. R.; Krzakowski, M.; Mauriac,
L.; Koralewski, P.; Vergote, I.; Webster, A.; Steinberg, M., and
von Euler, M. Journal of Clinical Oncology. 18(22):3748-3757, 2000
Nov 15.
Formestane
is feasible and effective in elderly breast cancer patients with
comorbidity and disability.
Venturino,
A.; Comandini, D.; Granetto, C.; Audisio, R. A.; Castiglione, F.;
Rosso, R., and Repetto, L. (Reprint available from:
Venturino
A PO S Lazzaro, Via P Belli 26 I-12051 Alba CN Italy). Breast Cancer
Research & Treatment. 62(3):217-222, 2000 Aug.
Critique
of survival update analysis from two phase III anastrozole clinical
trials.
Buzdar, A. U.; Wood; Wolter; Vogel; Bland, and Ravdin. Annals
of Surgical Oncology. 6(8 Suppl S):8S-11S, 1999 Dec. No abstract
Letrozole:
Which dose to be used?
Buzdar, A. U. Journal of Clinical Oncology. 18(8):1802-1803,
2000 Apr. No abstract
Top
of Page
Faslodex®
(fulvestrant, ICI182180): An estrogen receptor downregulator
Is
ICI 182,780 an antiprogestin in addition to being an antiestrogen?
Zand,
R. S. R.; Grass, L.; Magklara, A.; Jenkins, D. J. A., and Diamandis,
E. P. (Reprint available from: Zand RSR Mt Sinai Hosp, Dept Pathol
& Lab Med 600 Univ Ave Toronto ON M5G 1X5 Canada). Breast Cancer
Research & Treatment. 60(1):1-8, 2000 Mar.
Selective
estrogen receptor modulators: Structure, function, and clinical
use [Review].
Osborne,
C. K. and Fuqua, S. A. W. Journal of Clinical Oncology. 18(17):3172-3186,
2000 Sep.
Development
of a novel, "pure" antiestrogen.
Howell,
A.; Osborne, C. K.; Morris, C., and Wakeling, A. E. ICI 182,780
(Faslodex (TM)) -. Cancer. 89(4):817-825, 2000 Aug 15.
Similarities
and distinctions in the mode of action of different classes of antioestrogens
[Review].
Wakeling,
A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar.
Approaches
targeted to estrogen receptors for treatment of tamoxifen-resistant
breast cancer: A brief overview.
Terakawa, N. (Reprint available from: Terakawa N Tottori Univ,
Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan)..
Oncology. 59(Suppl 1):3-4, 2000. No abstract
Treatment
with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis
factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells.
Smolnikar,
K.; Loffek, S.; Schulz, T.; Michna, H., and Diel, P. (Reprint available
from: Smolnikar K DSHS Cologne, Inst Morphol & Tumor Res Carl
Diem Weg 6 D-50927 Cologne Germany). Breast Cancer Research &
Treatment. 63(3):249-259, 2000 Oct.
Symposium
overview: Estrogens and antiestrogens in managing the patient with
breast cancer.
Newman,
L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary,
S. E (Reprint available from: Singletary SE Univ Texas, MD Anderson
Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX
77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep.
Top
of Page
Ovarian
ablation/suppression
Combined
treatment with buserelin and tamoxifen in premenopausal metastatic
breast cancer: A randomized study.
Klijn,
J. G. M.; Beex LVAM; Mauriac, L.; van Zijl, J. A.; Veyret, C.; Wildiers,
J.; Jassem, J. Piccart, M.; Burghouts, J.; Becquart, D.; Seynaeve,
C.; Mignolet, F., and Duchateau, L. (Reprint available from: Klijn
JGM Dr Daniel den Hoed Klin, Rotterdam Canc Inst, Dept Med Oncol
Groene Hilledijk 301 NL-3075 EA Rotterdam Netherlands). Journal
of the National Cancer Institute. 92(11):903-911, 2000 Jun 7.
Prevention
of rat mammary carcinoma utilizing leuprolide as an equivalent to
oophorectomy.
Jett,
E. A.; Lerner, M. R.; Lightfoot, S. A.; Hanas, J. S.; Brackett,
D. J., and Hollingsworth, A. B. (Reprint available from: Hollingsworth
AB Mercy Hosp, Womens Ctr 4300 McAuley Blvd Oklahoma City, OK 73120
USA). Breast Cancer Research & Treatment. 58(2):131-136, 1999
Nov.
Combined
endocrine therapy for breast cancer - New life for an old idea?
Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins
Oncol Ctr 1650 Orleans St,Rm 409 Baltimore, MD 21231 USA). Journal
of the National Cancer Institute 92(11):859-860, 2000 Jun 7. No
abstract
Top
of Page
Estrogen/progesterone
receptors
The
effect of estrogen usage on the subsequent hormone receptor status
of primary breast cancer.
Lower,
E. E.; Blau, R.; Gazder, P., and Stahl, D. L. (Reprint available
from: Lower EE Univ Cincinnati, Coll Med, Dept Internal Med Cincinnati,
OH 45221 USA).. Breast Cancer Research & Treatment. 58(3):205-211,
1999 Dec.
Development
of a novel, "pure" antiestrogen.
Howell,
A.; Osborne, C. K.; Morris, C., and Wakeling, A. E. ICI 182,780
(Faslodex (TM)) -. Cancer. 89(4):817-825, 2000 Aug 15.
Time-dependent
relevance of steroid receptors in breast cancer.
Coradini,
D.; Daidone, M. G.; Boracchi, P.; Biganzoli, E.; Oriana, S.; Bresciani,
G.; Pellizzaro, C.; Tomasic, G.; Di Fronzo, G., and Marubini, E.
Journal of Clinical Oncology. 18(14):2702-2709, 2000 Jul.
Hormonal
receptor determination of 1,052 Chinese breast cancers.
Chow,
L. W. C. and Ho, P. Journal of Surgical Oncology. 75(3):172-175,
2000 Nov.
Youth
and hormone receptors in breast cancer: good or bad news first?
Stockler, M. and Beith, J. (Reprint available from: Stockler
M Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr,
Dept Med Sydney NSW 2006 Australia). Lancet. 355(9218): 1839-1840,
2000 May 27. No abstract
Top
of Page
|
